The CpG island methylator phenotype (CIMP), characterized by an exceptionally high frequency of methylation of discrete CpG islands, is observed in 18% to 25% of sporadic colorectal cancers. Another hypermethylation pattern found in colorectal cancers, termed long-range epigenetic silencing, is associated with DNA/histone methylation in three distinct gene clusters at chromosome 2q14.2, showing that DNA hypermethylation can span larger chromosomal domains and lead to the silencing of flanking, unmethylated genes. We investigated whether these two phenotypes are interrelated in colorectal cancers. The CIMP status of 148 sporadic colorectal cancers was determined by methylation-specific PCR. We determined the BRAF V600E mutation by mutant allele -specific PCR amplification. The methylation status of the MLH1 gene and of three CpG islands (EN1, SCTR, and INHBB), corresponding to three distinct clusters along 2q14.2, was determined by methylation-specific PCR. The average number of sites showing methylation in CIMP+ tumors was 2.21, compared with 1.22 for CIMPÀ individuals, and this difference was highly significant (P = 3.6 Â 10
Introduction
Experimental evidence accumulated in recent years indicates that transcriptional inactivation of tumor suppressor genes within promoter-associated CpG islands by cytosine methylation plays an important role in the formation and progression of human cancers (1) . Hypermethylation specifically localized in promoter regions is often observed in colorectal cancer and contributes to the silencing of a number of genes including tumor suppressor genes (e.g., CDKN2A, MLH1, MGMT, and APC; ref. 2) . In recent years, the role of this silencing mechanism in the etiology of colorectal cancer has increasingly been recognized. Toyota et al. (3) originally proposed that a subset of sporadic colorectal cancers display a promoter CpG island methylator phenotype (CIMP), which manifests itself as an exceptionally high frequency of methylation of discrete CpG islands. Although the existence of CIMP has been questioned by some investigators, very recent articles have definitively confirmed the presence of a subset of colorectal cancers associated with the CpG island methylation of a number of genes across the genome (4) (5) (6) . Sporadic colorectal tumors displaying CIMP are associated with proximal location, the female gender, older age, the BRAF V600E mutation, and the wild-type TP53 genotype. In addition, a high degree of microsatellite instability in CIMP+ tumors is associated with MLH1 hypermethylation (7, 8) .
Long-range epigenetic silencing (LRES), as originally proposed by Frigola et al. (9) , is another epigenetic mechanism found to be common in colorectal cancers and contributes to the silencing of a number of genes. Whereas CIMP+ is defined as methylation at several distinct loci and is reflective of a generalized hypermethylation within the genome, LRES is defined as the silencing of long chromosomal regions, leading to transcriptional repression not only of hypermethylated but also of unmethylated genes, lying either within or on the boundaries of silenced domain. This recent finding of Frigola et al. shows that epigenetic silencing is not solely a focal event but involves a 4-Mb domain of chromosome 2q14.2. Frigola et al. found that LRES at 2q14.2 was associated with DNA methylation in three enriched CpG island clusters. It has been discovered that DNA methylation in each of these clusters is associated with suppression of flanking unmethylated genes. Furthermore, the level of suppression of flanking unmethylated genes was much more pronounced in tumors that exhibited a higher number of hypermethylated CpG islands (EN1, SCTR, and INHBB), which correspond to three enriched CpG island clusters along chromosome 2q14.2. These data suggest that the extent and spread of DNA hypermethylation may influence the long-range suppression of neighboring genes (9) . A similar example of LRES was found recently in microsatelliteunstable sporadic colorectal cancers that displayed MLH1 promoter hypermethylation. A silenced region that corresponds to a cluster of genes flanking MLH1 was also associated with DNA/histone methylation and involved a 1.1-Mb domain of 3p22 (10) .
CIMP has been found to be associated with a significantly high frequency of hypermethylation of discrete CpG islands, in contrast to LRES, which has an effect on the repression of multiple rather than single genes. We hypothesized that CIMP+ tumors may display a higher level of CpG island hypermethylation across chromosome band 2q14.2 as compared with CIMPÀ tumors. Therefore, our study aimed at clarifying the issue of whether there are differences between CIMP+ and CIMPÀ sporadic colorectal cancers with respect to the extent of DNA hypermethylation over the 2q14.2 band.
We found that all the CIMP+ tumors (confirmed by MLH1 methylation and BRAF mutation) showed hypermethylation of at least one of the loci studied, in contrast to CIMPÀ tumors. More importantly, CIMP+ tumors displayed an exceptionally high number of methylated sites along 2q14.2 compared with CIMPÀ tumors. Our data indicate that in CIMP+ tumors the number of hypermethylated CpG islands at 2q14.2 is substantally higher than in CIMPÀ ones. This difference may FIGURE 1. Representative methylation-specific PCR for CIMP marker panel, MLH1 gene, and three CpG islands associated with EN1, SCTR , and INHBB genes. PCR products were amplified with methylated (M ) and unmethylated (U ) sequencespecific primers. Distilled water (H 2 O ) was used as a blank control. Bisulfite-treated DNA from normal lymphocytes (NL ) and the same DNA methylated by Sss I methylase (SssI NL ) served as methylated and unmethylated control sequences, respectively. HyperLadder V (Bioline) was used as a molecular weight marker (MW).
possibly contribute to a wider range of silenced genes by LRES in CIMP+ than in CIMPÀ tumors.
Results

CIMP
We examined the CIMP status of 148 sporadic colorectal cancer specimens by methylation-specific PCR with a CIMPspecific marker panel (4) . The overall results of the CIMP analysis are presented in Table 2 . Methylation of CACNA1G, IGF2, NEUROG1, RUNX3, and SOCS1 was detected in 39%, 22%, 36%, 30%, and 22% of tumors, respectively. Figure 1 shows representative results of methylation-specific PCR for nine genes. Figure 2 illustrates the distribution of the number of methylated loci from the CIMP-specific marker panel.
Because CIMP was defined as having at least three methylated sites of the five studied loci, 23% (n = 34) of the tumors were classified as CIMP+. A strongly bimodal distribution of tumors according to the number of methylated loci was observed (Fig. 2) . The mean age of patients with CIMP+ tumors was higher (67.8 years) than of those with CIMPÀ tumors (63.2 years; Table 1 ). There was a significant association between age and CIMP (P = 0.03). There was no significant association between CIMP and gender as reported by others (P = 0.7; refs. 4, 5, 11).
BRAF V600E Mutation and MLH1 Methylation in CIMP+ and CIMPÀ Samples
Recent studies in which the MethyLight technique was used to determine CIMP status have indicated significant relationships between the BRAF V600E mutation, MLH1 methylation, and CIMP (4, 5) . In contrast to MethyLight, methylationspecific PCR is considered to be a less specific and sensitive technique. Therefore, to examine whether our CIMP classification is appropriate, we decided to determine the presence of the BRAF V600E mutation and MLH1 methylation. As depicted in Table 2 , we observed a significant association of both the BRAF V600E mutation (P = 5.1 Â 10
À7
) and MLH1 methylation (P = 1.6 Â 10
À5
) with CIMP+ tumors.
The DNA Methylation Status of Three CpG Islands along the 2q14.2 Region in Colorectal Cancers According to CIMP Status
To study the interaction between CIMP and hypermethylation along 2q14.2, we analyzed the methylation status of three CpG islands (associated with EN1, SCTR, and INHBB genes) representing three clusters of heavily methylated CpG islands in the 2q14.2 band (9).
We did not find any association between the three CpG islands examined and either age or sex (data not shown). The results of the methylation status of the CpG islands associated with the EN1, SCTR, and INHBB genes are presented in Table 3 and Fig. 3 .
Our analysis revealed that hypermethylation of at least one of the CpG islands within 2q14.2 is a very common event in our colorectal cancer samples and was found in 88% (130 of 148) of cases. The frequency of hypermethylated genes varied from 33% for EN1 and 30% for INHBB to 81% for SCTR. The methylation frequency of EN1, SCTR, and INHBB was significantly associated with CIMP-positive tumors (P = 3.2 Â 10
À7
, P = 0.002, and P = 0.006, respectively). The distribution of the total number of hypermethylated CpG islands differed significantly according to CIMP status (P = 1.3 Â 10
À9
, m 2 goodness-of-fit test) and the mean number of methylated sites was 2.21 among CIMP+ individuals as compared with 1.22 among CIMPÀ individuals (P = 3.6 Â 10
À8
, Mann-Whitney test). In particular, we found that 100% (34 of 34) of the CIMP+ tumors showed hypermethylation of at least one of the studied loci, in contrast to CIMPÀ tumors, where 16% (18 of 114) of the NOTE: Sensitivity was defined as (n of CIMP+ tumors for a given marker) / (n of all CIMP+ cases). Specificity was defined as (n of CIMPÀ tumors negative for given marker) / (n of all CIMPÀ cases). *P value was calculated using t test. cP value was calculated using Fisher's exact test.
tumors remained unmethylated at each of the three examined sites. More importantly, CIMP+ tumors displayed an exceptionally high frequency of concordant hypermethylation of all three CpG islands studied (16 of 34; 47%) compared with CIMPÀ tumors (3 of 114; 3%).
Discussion
During the past decade, the most widely studied epigenetic abnormality in tumor development has been the inactivation of tumor suppressor genes by DNA hypermethylation in promoter regions (12) (13) (14) . Although what determines which loci are affected remains unexplained, it has become clear that in many tumors some genes show an exceptionally increased frequency of DNA methylation. This is particularly apparent in colorectal cancer where incidence of hypermethylation of any given gene seems to be much higher than for mutations and where a CIMP was described for the first time (15, 16) . Although the presence of such a phenotype in colorectal cancer has been questioned by some groups, recent research has clearly confirmed the existence of CIMP (17) . This was made possible by the use of a newly established marker panel (CACNA1G, IGF2, NEUROG1, RUNX3, and SOCS1) to classify tumors as either CIMP+ or CIMPÀ, along with additional genetic and epigenetic criteria (4, 6) . Apart from a high frequency of methylation of discrete CpG islands, tumors displaying CIMP are characterized by a high frequency of the BRAF V600E mutation, a high degree of microsatellite instability associated with MLH1 hypermethylation, proximal location, the female gender, and older age (4, 7, 8) .
We used methylation-specific PCR to determine CIMP status. This is considered to be a less precise technique than the recently developed MethyLight quantitative PCR (5, 18) . Therefore, we determined the presence of the BRAF V600E mutation and MLH1 methylation in our cohort to see whether our CIMP classification was appropriate. We observed a significant association between the BRAF mutation, MLH1 methylation, and CIMP (P = 5.1 Â 10
À7
and P = 1.6 Â 10 À5 , respectively).
The frequency of BRAF mutation observed in our CIMP+ group (40%) was similar to that observed by Samowitz et al. (5) . Moreover, the authors cannot exclude the population differences in relation of CIMP and BRAF mutation. To the authors' knowledge, this is the first CIMP study among European population.
The observation of the strongly bimodal distribution of the number of methylated tumors in our cohort, as well as the relatively high sensitivity (ranging from 73% to 97% for SOCS1 and RUNX3, respectively) and specificity (ranging from 77% to 96% for CACNA1G and IGF2, respectively) of the markers used, is fully consistent with the results of other groups (4, 5, 7) .
Recent data show that, apart from DNA methylation, chromatin modifications are also involved in aberrant gene silencing in tumorigenesis (9, 10, 19) . One example of such epigenetic suppression comes from studies on colorectal cancers and colorectal cancer cell lines. LRES, which was (H3-K9) independently of DNA methylation. However, the level of suppression of flanking unmethylated genes was much more pronounced in tumors that exhibited a higher number of hypermethylated CpG islands (EN1, SCTR and INHBB), which correspond to three enriched CpG island clusters found at 2q14.2 (9) .
Given that CIMP probably reflects the global epigenetic status of a cell, we examined the mutual relationships between widespread CpG methylation across the genome (by use of five marker panel) and LRES by investigating the methylation of three markers (EN1, SCTR, and INHBB) along the 2q14.2 band.
Our results show that there are two significant differences between CIMP+ and CIMPÀ tumors with regard to DNA methylation in the 2q14.2 band. All CIMP+ samples displayed at least one hypermethylated locus as opposed to CIMPÀ samples, where a substantial fraction (16%) of tumors were unmethylated at the studied CpG islands. More importantly, almost all the cases of simultaneous hypermethylation of all three CpG islands occurred in CIMP+ individuals (P = 1.3 Â 10
À9
; Table 3 ). It is particularly noteworthy that the mean number of methylated sites along 2q14.2 was clearly higher for CIMP+ individuals than for CIMPÀ individuals (P = 3.6 Â 10
À8
). Frigola et al. (9) indicated that when simultaneous hypermethylation of these three CpG islands was displayed by a tumor, pronounced suppression was also observed for unmethylated genes located at the boundaries of the 2q14.2 band. This observation is of particular importance in connection with our results because there are several genes located at the boundaries of 2q14.2, which may play a role in colorectal carcinogenesis. DDX18 (MrDB), located close to the boundary with 2q14.1, codes for an RNA-dependent helicase that is activated by c-MYC proto-oncogene and plays a role in cell growth (20) . The GLI2, CLASP1, and TSN genes are located close to the boundary with 2q14.3. GLI2 is a known oncogene that belongs to the sonic hedgehog signaling pathway, which plays a critical role in the regulation of the development of cancer and is associated with basal cell carcinoma and breast cancer. GLI2 also regulates the expression of the antiapoptotic factor BCL2 (21-23). CLASP1 has a function in mitosis, preventing aneuploidy by controlling spindle and kinetochore functioning (24) . TSP (translin) recognizes ssDNA ends and probably plays a role in damage recognition (25) . It also should be noted that the EN1 (engrailed 1) gene located in one of the hypermethylated domains within the 2q14.2 band used by us as a methylation marker plays a role in the Wnt signaling pathway, which is involved in colorectal carcinogenesis (26, 27) .
Our data suggest that CIMP+ tumors differ from CIMPÀ tumors with respect not only to CpG methylation but also to a wider range of suppressed genes within the 2q14.2 band. This difference may significantly contribute to reducing the expression of genes located at the boundaries of the silenced domain. It will be of particular interest to examine whether this difference relates only to the 2q14.2 band or whether this phenomenon plays a role in regions beyond chromosome 2, as recently described for colorectal, breast, head and neck, bladder, esophageal, and lung cancers (10, 28, 29) . Notably, a very recent article by Hitchins et al. (10) describes a similar LRES where a whole region located in 3p22 spanning 1.1 Mb was transcriptionally suppressed in microsatellite-unstable sporadic colorectal cancers that displayed MLH1 promoter hypermethylation. Given that MLH1 methylation -associated microsatellite instability generally does not occur among sporadic colorectal cancers outside the context of CIMP, it can be hypothesized that LRES across 3p22 is specific to CIMP (4, 10) . This finding together with our results further raises the possibility that CIMP+ tumors tend to be more prone to LRES because of a tight connection of CpG islands and histone (H3-K9) methylation in the mechanism of regional epigenetic silencing.
Nevertheless, the fact that the boundaries of the 2q14.2 band harbor both possible tumor suppressor genes and a known oncogene may contribute through a significant difference in DNA methylation to the specific characteristics of the CIMP and its clinicopathologic features.
Materials and Methods
Patients and Samples
Surgically resected frozen tissues of colorectal cancers were obtained from the Second Department of General and Oncological Surgery, Wroclaw Medical University. The tumors analyzed represent a cohort of 148 sporadic colorectal cancer. Only patients with primary colorectal cancer who had not received preoperative therapy were included. The study was accepted by the Wroclaw Medical University Ethics Committee. Genomic DNA was prepared using standard phenolchloroform extraction and ethanol precipitation.
Detection of BRAF V600E Mutation
Mutant allele-specific PCR was used to detect BRAF V600E mutation as previously described (30) . Briefly, two different forward primers with a single base substituted at the end of the primer (5 ¶-GTGATTTTGGTCTAGCTACAGT-3 ¶ and 5 ¶-GTGATTTTGGTCTAGCTACAGA-3 ¶) were used to amplify the wild-type allele and BRAF mutation, respectively. The sequence of the common reverse primer used for both reactions was 5 ¶-GGCCAAAAATTTAATCAGTGGA-3 ¶. Both PCR reactions were done separately in a 25-AL reaction volume containing 1Â PCR buffer (Qiagen), 1.5 mmol/L MgCl 2 , 200 Amol/L deoxynucleoside triphosphate, 40 ng of genomic DNA, 0.2 Amol/L of each primer, and 0.75 units of Taq DNA polymerase (Qiagen). Both PCR reactions were set with an initial denaturation of 2 min at 95jC and subsequent denaturation for 30 s at 94jC, annealing for 30s at 64jC, and extension for 30s at 72jC in a PTC 200 DNA Engine Thermal cycler (MJ Research, Inc.). Thirty-five cycles were used to amplify the PCR product with an expected size of 125 bp. Because mutant allele -specific PCR amplification carries the risk of false-positive/false-negative results, special precautions were taken and all samples were reexamined for the BRAF V600E mutation at least twice.
Bisulfite Treatment of DNA and Methylation-Specific PCR
Bisulfite treatment of genomic DNA obtained from resected frozen tissues was carried out based on the method developed by Herman et al. (31) with minor modifications described by Chan et al. (32) .
In brief, 1 Ag of genomic DNA was denatured with 2 mol/L NaOH at 37jC for 10 min, followed by incubation with 3 mol/L sodium bisulfite (pH 5.0) at 50jC for 16 h in the dark. DNA was then purified using the DNA Isolation Kit (Biological Industries) as recommended by the manufacturer, incubated with 3 mol/L NaOH at room temperature for 5 min, precipitated with 10 mol/L ammonium acetate and 100% ethanol, washed with 70% ethanol, and finally resuspended in 20 AL of distilled water.
Approximately 50 ng of the modified DNA were used as a template for methylation-specific PCR amplifications with primers specific to either the methylated or unmethylated promoter sequences. The primer sequences, annealing temperatures, and expected product sizes are listed in Table 4 Human blood DNA from a healthy subject methylated by SssI methylase (New England Biolabs) was used as a positive control for the methylated primer set in each PCR reaction, and untreated bisulfite-modified genomic DNA from the same subject was used as a positive control for the unmethylated reaction. A water blank was used as a negative control for the PCR amplifications. The amplification products were separated on a 2.5% agarose gel and visualized by ethidium bromide staining and UV transillumination.
CIMP
We characterized the CIMP status of 148 sporadic colorectal cancers by methylation-specific PCR using a panel of methylation markers (Table 4) including CACNA1G (the 1G subunit of the voltage-dependent T type calcium channel), IGF2 (insulin-like growth factor 2), NEUROG1 (neurogenin 1), RUNX3 (runt-related transcription factor 3), and SOCS1 (suppressor of cytokine signaling 1), described recently by Weisenberger et al. (4) . The use of these five markers has been shown to have very high accuracy, specificity, and sensitivity for the determination of overall CIMP status (4, 6) . CIMP+ was defined as the presence of z3 methylated CpG islands of the panel of five, CIMPÀ as the presence of, at most, 2 methylated CpG islands (6) .
Methylation along the 2q14.2
To determine DNA methylation along the 2q14.2, we used methylation-specific PCR with the following three markers: EN1 (engrailed-1), SCTR (secretin receptor), and INHBB (inhibin hb). These markers correspond to three distinct regions of extensive hypermethylation within the 2q14.2 band in colorectal cancers and served altogether as a hallmark of hypermethylation at the analyzed region (9).
Statistical Analysis
When using 2 Â 2 contingency tables for categorical data, Fisher's exact test was used. The Mann-Whitney test was used to compare the mean number of methylated sites in CIMP+ and CIMPÀ patients. The Marascuilo procedure for comparing multiple proportions was used to correct for the effects of multiple testing. All P values were two sided and P V 0.05 was considered significant.
